Treatment of Epidermolysis Bullosa Simplex, Weber-Cockayne Type, With Botulinum Toxin Type A

Roxanne J. Abitbol, MD; Linda Hua Zhou, MD; Department of Dermatology and Skin Surgery, Roger Williams Medical Center, Providence, Rhode Island

The Cutting Edge: Challenges in Medical and Surgical Therapeutics

REPORT OF A CASE

A 43-year-old white woman with a history of epidermolysis bullosa simplex (EBS), Weber-Cockayne type (EBS-WC), which she had had since childhood, presented with multiple blisters, erosions, and crusts on the bottom of both feet (Figure 1). During most of her life, new blisters would arise and then heal after several weeks. Severe flares would occur during the summer months and on vacations to warm climates. Previous treatments included aluminum chloride and tetracycline. The patient's mother, sister, and son also had a history of EBS-WC. Her medical history was otherwise unremarkable. The only medication she was taking was an oral contraceptive pill, and she reported a drug allergy to penicillin.

Physical examination revealed a total of 17 blisters and erosions measuring 0.5 to 3.0 cm on the plantar aspect of the feet. The hands and the rest of the skin were clear. A lesion had previously been biopsied, and the findings confirmed a diagnosis of EBS-WC.

SOLUTION

One foot of our patient was treated with BTX-A injections, and the other (control) foot received injections of isotonic sodium chloride (normal saline) solution. First, a Minor iodine-starch test was performed to reveal the

Figure 1. Patient’s feet before treatment.
areas of high sweating. Then, analgesia of the soles was achieved by blocking the posterior tibial nerve and the sural nerve. Lidocaine (4 mL), 2%, was injected posterior to the pulse of the tibial artery and between the Achilles tendon and the superior border of the lateral malleolus. One bottle of BTX-A was diluted with 10 mL of preserved sterile saline (1 U/0.1 mL); then, 0.1 mL of BTX-A was injected into the middle to deep dermis on the plantar aspect of the right foot at 1-cm intervals. A total of 100 U were used. The lateral aspect of the foot and the area between the toes were not treated. The approximate area of the right foot that received the BTX-A injections was 166.5 cm². The left foot, which served as a control, only received injections of preserved sterile saline, without any toxin. The investigators were blinded and did not know which foot had received the BTX-A during the entire length of the study. The study was approved by the institutional review board committee at Roger Williams Hospital, Providence, Rhode Island. The patient signed a consent form, as well as a photography release form, before the treatment visit. The BTX-A was provided by the Department of Dermatology at Roger Williams Medical Center.

The patient was followed up for 3 months. She tolerated the procedure extremely well and did not experience any adverse events from the injections. She did not develop any bruising, hematomas, or increase in blisters. After 2 weeks, she reported a decrease in pain and perspiration on the right foot, which had received the BTX-A. Also, she noted a decrease in blister formation on the BTX-A–treated foot. All blisters were traced, and then the area was calculated with a digital wound measurement device (Visitrac; Smith & Nephew, Largo, Florida). The foot that received the BTX-A injections had fewer blisters than the control foot. The mean area of blister formation after therapy was 3.57 cm² in the treated foot and 5.41 cm² in the control foot. These values represented a 34% difference between the treated and the nontreated feet. The mean number of blisters was 6.57 in the foot treated with BTX-A and 8.42 in the control foot. Before treatment, the foot that would receive the BTX-A had 11 blisters and a total blister area of 4.6 cm², while the control foot had 6 blisters and a total blister area of 2.6 cm². Three weeks after treatment, a therapeutic benefit was already noticeable in the treated foot. In the control foot, however, newly formed blisters were still evident (Figure 2). At the end of 3 months, the BTX-A–treated foot had 4 blisters, with a total blister area of 1.6 cm², while the control foot had 9 blisters, with a total blister area of 2.4 cm². These values represented a 64% decrease in the number of blisters and a 65% reduction in blister surface area in the treated foot (Table). Most of the blisters that did develop in the BTX-A–treated foot occurred on the lateral edges and between the toes, not on the plantar aspect. This represented areas of the foot that did not receive the BTX-A injections.

**COMMENT**

Inherited epidermolysis bullosa comprises a group of rare genetic disorders that are characterized by the development of blisters after minor trauma to the skin. There are 3 major categories: simplex, junctional, and dystrophic. There are more than 25 known forms within these categories and more than 10 different gene mutations for proteins that normally reside in the epidermis, dermoepidermal junction, and superficial papillary dermis.

Epidermolysis bullosa simplex is usually inherited in an autosomal dominant manner and results from the genetic mutation of keratins 5 and 14, which are interme-

---

**Table. Blister Data Before and After Treatment With Botulinum Toxin Type A**

<table>
<thead>
<tr>
<th>Foot</th>
<th>No. of Blisters</th>
<th>Surface Area, cm²</th>
<th>No. of Blisters</th>
<th>Surface Area, cm²</th>
<th>Difference in No. of Blisters, %</th>
<th>Difference in Blister Surface Area, %</th>
<th>Mean Blister Surface Area, cm²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right</td>
<td>11</td>
<td>4.6</td>
<td>4</td>
<td>1.6</td>
<td>64 (↓)</td>
<td>65 (↓)</td>
<td>3.57</td>
</tr>
<tr>
<td>Left</td>
<td>6</td>
<td>2.6</td>
<td>9</td>
<td>2.4</td>
<td>50 (↑)</td>
<td>8 (↓)</td>
<td>5.41</td>
</tr>
</tbody>
</table>
diate filaments that are normally present in the basal layer of the epidermis. This mutation in turn produces a weakness in keratinocyte adhesion and subsequently leads to blister formation within the lower part of the epidermis. Epidermolysis bullosa simplex can be further divided into the following subtypes: localized, or EBS-WC; generalized, or Koebner EBS; herpetiform, or Dowling-Meara EBS; EBS with mottled pigmentation; and EBS with muscular dystrophy.

A recurrent blistering eruption of the hands and feet after frictional trauma is characteristic of EBS-WC. Exacerbations and increased blister formation occur during hot weather, prolonged walking, or physical activity. Hyperhidrosis is a common associated finding. The increase in blister development that occurs during hot summer months is thought to be attributable to an increase in the coefficient of friction of the skin caused by sweating and raised skin temperature. The Weber-Cockayne type of EBS is caused by a genetic mutation in the keratin intermediate filaments 5 and 14 in the basal layer of the epidermis. Increased mechanical stress, which often occurs when hyperhidrosis is present, then leads to blister formation.

Historically, EBS has been difficult to treat. Treatment has been aimed at preventing blister formation with appropriate wound dressings, preventing inflammation and bacterial superinfection with oral antibiotics, and decreasing sweating with aluminum chloride therapy. The present case illustrates that BTX-A may play a role in the treatment of EBS-WC. The mechanism of action of BTX-A involves blockage of the cholinergic nerve terminals and inhibition of the release of acetylcholine. As well as acting at the neuromuscular junction, BTX-A also blocks the autonomic cholinergic junctions of the post-ganglionic sympathetic fibers to the sweat glands, making it an ideal therapy for hyperhidrosis. There have been a few reported adverse effects after local injections of BTX-A, including weakness in the muscles adjacent to the treatment sites. Beneficial results last for 4 months but may continue for up to 1 year.

This article presents only 1 case of BTX-A–treated EBS-WC, but the results look promising. Although a 64% reduction in blister count appears clinically significant, larger case-controlled, double-blinded studies are needed to further elucidate these results. Also, using a higher concentration of BTX-A, such as 2 U/0.1 mL, for a total of 150 to 200 U per foot, may be more effective. Furthermore, treatment should not be limited to the plantar aspect of the foot, it should also involve the lateral surface and the area between the toes. We hope that this case report stimulates the production of further studies of this nature.

Accepted for Publication: January 28, 2008.
Correspondence: Roxanne J. Abitbol, MD, South Nassau Dermatology, 258 Merrick Rd, Oceanside, NY 11772 (RoxanneAbitbol@hotmail.com).

Author Contributions: Dr Abitbol had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Abitbol.
Acquisition of data: Abitbol and Zhou.
Analysis and interpretation of data: Abitbol and Zhou.
Drafting of the manuscript: Abitbol.
Critical revision of the manuscript for important intellectual content: Abitbol and Zhou.
Administrative, technical, and material support: Abitbol.
Study supervision: Zhou.

Financial Disclosure: None reported.

Funding/Support: The Department of Dermatology and Skin Surgery, Roger Williams Medical Center, provided the medication and supplies for this study.

Role of the Sponsors: The sponsor had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Additional Contributions: Polly Carson assisted with the institutional review board approval process for this study.

REFERENCES